Overview
Allegro is a family of patients and scientists dedicated to designing disruptive technologies. The company's mission is to develop first-in-class technology with blockbuster potential addressing unmet clinical needs in orthopedics, with pipeline candidates designed to challenge the status quo.
Key people
In the news
- 𝐖𝐡𝐚𝐭'𝐬 𝐭𝐡𝐞 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐨𝐬𝐭𝐞𝐨𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬 𝐚𝐧𝐝 𝐫𝐡𝐞𝐮𝐦𝐚𝐭𝐨𝐢𝐝 𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬?" One of the first questions we received during the Q&A session at the Flanders Technology & Innovation Festival It's a great question because many people use the terms interchangeably, while they are actually very different conditions. 🔹 𝐎𝐬𝐭𝐞𝐨𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬 is the most common form of arthritis. It is a degenerative joint disease in which the structures inside the joint gradually
- 𝐓𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐥𝐨𝐧𝐠𝐞𝐯𝐢𝐭𝐲 𝐢𝐬 𝐚𝐛𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐚𝐝𝐝𝐢𝐧𝐠 𝐲𝐞𝐚𝐫𝐬 𝐭𝐨 𝐥𝐢𝐟𝐞. 𝐈𝐭'𝐬 𝐚𝐛𝐨𝐮𝐭 𝐚𝐝𝐝𝐢𝐧𝐠 𝐥𝐢𝐟𝐞 𝐭𝐨 𝐲𝐞𝐚𝐫𝐬. That is the conversation our CEO and Co-Founder Lucas Decuypere will be joining at 𝐌𝐞𝐝𝐓𝐞𝐜𝐡 𝐖𝐨𝐫𝐥𝐝 𝐄𝐮𝐫𝐨𝐩𝐞 in Valletta, Malta, as part of the panel: 🎤 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠 𝐢𝐧 𝐋𝐨𝐧𝐠𝐞𝐯𝐢𝐭𝐲: 𝐅𝐫𝐨𝐦 𝐁𝐢𝐨𝐡𝐚𝐜𝐤𝐢𝐧𝐠 𝐭𝐨 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 📅 Friday, 13 November | 12:15–12:55 As the longevity field evolves from consumer
- 𝐂𝐚𝐧 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐡𝐞𝐥𝐩 𝐮𝐬 𝐬𝐭𝐚𝐲 𝐚𝐜𝐭𝐢𝐯𝐞 𝐟𝐨𝐫 𝐥𝐨𝐧𝐠𝐞𝐫? On 24 October, our CEO and Co-Founder Lucas Decuypere will be at 𝐅𝐓𝐈 𝐅𝐞𝐬𝐭𝐢𝐯𝐚𝐥 to discuss one of the most important challenges in healthy aging: 🎤 "𝐇𝐨𝐰 𝐜𝐚𝐧 𝐰𝐞 𝐟𝐢𝐠𝐡𝐭 𝐨𝐬𝐭𝐞𝐨𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬 𝐚𝐧𝐝 𝐬𝐭𝐚𝐲 𝐚𝐜𝐭𝐢𝐯𝐞?" Join the conversation on how technology is reshaping the future of mobility, sport and health. 📍 Antwerp Central Station 📅 24 October 2026 🕦 11:30 – 12:10 Because living longer only matters if you can
- 𝐖𝐡𝐚𝐭 𝐚 𝐰𝐞𝐞𝐤 𝐢𝐧 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚! 𝐋𝐒𝐈 𝐄𝐮𝐫𝐨𝐩𝐞 ’26 𝐛𝐫𝐨𝐮𝐠𝐡𝐭 𝐞𝐱𝐚𝐜𝐭𝐥𝐲 𝐰𝐡𝐚𝐭 𝐰𝐞 𝐜𝐚𝐦𝐞 𝐟𝐨𝐫: 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧𝐬, 𝐬𝐭𝐫𝐨𝐧𝐠 𝐜𝐨𝐧𝐧𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐫𝐞𝐚𝐥 𝐞𝐱𝐜𝐢𝐭𝐞𝐦𝐞𝐧𝐭 𝐚𝐫𝐨𝐮𝐧𝐝 𝐰𝐡𝐚𝐭 𝐰𝐞 𝐚𝐫𝐞 𝐛𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐚𝐭 𝐀𝐥𝐥𝐞𝐠𝐫𝐨 𝐁𝐢𝐨𝐭𝐞𝐜𝐡. Our CEO and Co-Founder Lucas Decuypere took the stage to present Allegro and Hydrocelin to the medtech and investment community. A few highlights: 👉 Strong engagement with investors and
- 𝐖𝐡𝐚𝐭 𝐚 𝐰𝐞𝐞𝐤 𝐢𝐧 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚! 𝐋𝐒𝐈 𝐄𝐮𝐫𝐨𝐩𝐞 ’26 𝐛𝐫𝐨𝐮𝐠𝐡𝐭 𝐞𝐱𝐚𝐜𝐭𝐥𝐲 𝐰𝐡𝐚𝐭 𝐰𝐞 𝐜𝐚𝐦𝐞 𝐟𝐨𝐫: 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧𝐬, 𝐬𝐭𝐫𝐨𝐧𝐠 𝐜𝐨𝐧𝐧𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐫𝐞𝐚𝐥 𝐞𝐱𝐜𝐢𝐭𝐞𝐦𝐞𝐧𝐭 𝐚𝐫𝐨𝐮𝐧𝐝 𝐰𝐡𝐚𝐭 𝐰𝐞 𝐚𝐫𝐞 𝐛𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐚𝐭 𝐀𝐥𝐥𝐞𝐠𝐫𝐨 𝐁𝐢𝐨𝐭𝐞𝐜𝐡. Our CEO and Co-Founder Lucas Decuypere took the stage to present Allegro and Hydrocelin to the medtech and investment community. A few highlights: 👉 Strong engagement with investors and
- 𝐍𝐞𝐚𝐫𝐥𝐲 600 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐩𝐞𝐨𝐩𝐥𝐞 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞 𝐰𝐞𝐫𝐞 𝐥𝐢𝐯𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐨𝐬𝐭𝐞𝐨𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬 𝐢𝐧 2020. 𝐁𝐲 2050, 𝐭𝐡𝐚𝐭 𝐧𝐮𝐦𝐛𝐞𝐫 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 1 𝐛𝐢𝐥𝐥𝐢𝐨𝐧. Research published in The Lancet Rheumatology highlights ageing populations, population growth and obesity among the key drivers behind this growing burden. So why does such a widespread disease still have such a significant treatment gap? That is one of the topics our CEO Lucas Decuypere discusses with
- 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚 𝐥𝐚𝐬𝐭 𝐰𝐞𝐞𝐤. 🇨🇭 𝐁𝐚𝐬𝐞𝐥 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤. 𝐓𝐡𝐞 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧𝐬 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞. Lucas Decuypere, CEO and Co-Founder of Allegro Biotech, will be at the 26th Annual Biotech in Europe Forum on 7–8 October, connecting with investors, industry leaders and potential partners from across the life sciences ecosystem. If you’re attending and want to hear more about Allegro and Hydrocelin, let’s connect in Basel. Sachs Associates #SachsBEF #Biotech #MedTech #LifeSciences
- Lucas Decuypere is at LSI Europe ’26 Emerging Medtech Summit in Barcelona this week! 🇪🇸 Two opportunities to catch our CEO and Co-Founder on stage: 🎤 Tuesday | 3:00–3:15 PM Lucas Decuypere will present Allegro and share how we are advancing Hydrocelin, our patented injectable nanotechnology for knee osteoarthritis. 🎙️ Wednesday, September 30 | 5:15 PM | Living Room C Lucas Decuypere joins Lee Fleisher, CEO of Rubrum Advising, and Colby Holtshouse, President & CEO of May Health, for: “Demystifying Working with the FDA and CMS” For
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.